Alzamend Neuro
Biotechnology ResearchGeorgia, United States2-10 Employees
Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing therapies for Alzheimer’s disease as well as mood and stress-related disorders, including bipolar disorder, major depressive disorder, and PTSD. The company aims to provide treatments intended to address the needs of patients suffering from these conditions, collaborating with established medical centers to advance its two lead candidates through clinical trials. Based in Atlanta, Georgia, the organization operates within the biotechnology research sector, positioning itself as a developer of novel therapeutic approaches intended to complement or extend existing options in neuropsychiatric care. Its activities include advancing AL001, a lithium-delivery program, and ALZN002, a cell-based therapeutic vaccine approach, through collaborative clinical programs, notably with Massachusetts General Hospital. Recent developments include the initiation of a Phase II study for AL001 in bipolar disorder in collaboration with Mass General Hospital, reflecting ongoing progress in its trial portfolio while maintaining focus on bringing new treatments to patients. The company maintains a relatively small operation and engages with partners to support its clinical development programs.
1-888-653-2347 
support@leadiq.com 
